Literature DB >> 9168834

Maturational regulation and regional induction of cyclooxygenase-2 in rat brain: implications for Alzheimer's disease.

G Tocco1, J Freire-Moar, S S Schreiber, S H Sakhi, P S Aisen, G M Pasinetti.   

Abstract

We explored the constitutive expression, maturational regulation, and relation to kainic-acid-induced apoptosis of cyclooxygenase (COX)-2 mRNA in rat brain. In adult rats, COX-2 mRNA was expressed primarily in limbic structures. Constitutive COX-2 mRNA expression increased markedly between Postnatal Day 7 (P7) and P14, reaching adult levels by P21. Despite intense KA-induced seizures, no COX-2 mRNA induction was found before P14 in any brain region examined. During response to KA-induced seizures in adult brain, COX-2 mRNA induction paralleled temporally and overlapped anatomically the appearance of cellular morphological features of apoptosis in subsets of cells of the pyramidal neuron layer of the hippocampal formation, amygdaloid complex, and pyriform cortex. While COX-2 mRNA showed KA-induced elevation in the granule cell layer of the dentate gyrus, no detectable morphological features of apoptosis were found in this region. Finally, monotypic culture of rat corticohippocampal neurons confirmed the neuronal expression of COX-2 in vitro and revealed that COX-2 is induced during response to glutamate treatment, leading to neuron death. These studies may provide novel insights into the role of COX-2 and mechanisms of action of nonsteroidal anti-inflammatory drugs in Alzheimer's disease.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9168834     DOI: 10.1006/exnr.1997.6429

Source DB:  PubMed          Journal:  Exp Neurol        ISSN: 0014-4886            Impact factor:   5.330


  33 in total

Review 1.  Potential future neuroprotective therapies for neurodegenerative disorders and stroke.

Authors:  Rawan Tarawneh; James E Galvin
Journal:  Clin Geriatr Med       Date:  2010-02       Impact factor: 3.076

2.  Microsomal prostaglandin E synthase-2: cellular distribution and expression in Alzheimer's disease.

Authors:  Uzma Chaudhry; Hean Zhuang; Sylvain Doré
Journal:  Exp Neurol       Date:  2009-08-05       Impact factor: 5.330

3.  Cyclooxygenase-2 immunoreactivity and protein level in the gerbil hippocampus during normal aging.

Authors:  Choong Hyun Lee; Ki-Yeon Yoo; Jung Hoon Choi; Ok Kyu Park; In Koo Hwang; Il-Jun Kang; Moo-Ho Won
Journal:  Neurochem Res       Date:  2009-07-12       Impact factor: 3.996

Review 4.  Glucocorticoids in Alzheimer's disease. The story so far.

Authors:  P S Aisen; G M Pasinetti
Journal:  Drugs Aging       Date:  1998-01       Impact factor: 3.923

Review 5.  Antiinflammatory and neuroprotective actions of COX2 inhibitors in the injured brain.

Authors:  Kenneth I Strauss
Journal:  Brain Behav Immun       Date:  2007-11-08       Impact factor: 7.217

Review 6.  Discovery of a new function of cyclooxygenase (COX)-2: COX-2 is a cardioprotective protein that alleviates ischemia/reperfusion injury and mediates the late phase of preconditioning.

Authors:  Roberto Bolli; Ken Shinmura; Xian-Liang Tang; Eitaro Kodani; Yu-Ting Xuan; Yiru Guo; Buddhadeb Dawn
Journal:  Cardiovasc Res       Date:  2002-08-15       Impact factor: 10.787

7.  Geniposide attenuates epilepsy symptoms in a mouse model through the PI3K/Akt/GSK-3β signaling pathway.

Authors:  Hongtao Wei; Guanghui Duan; Jianxun He; Qinglong Meng; Yuxian Liu; Wanqiang Chen; Yongpeng Meng
Journal:  Exp Ther Med       Date:  2017-11-14       Impact factor: 2.447

Review 8.  Anti-inflammatory agents in Alzheimer's disease.

Authors:  Paul S Aisen
Journal:  Curr Neurol Neurosci Rep       Date:  2002-09       Impact factor: 5.081

Review 9.  [Clinical pharmacology of the selective COX-2 inhibitors].

Authors:  M Burian; G Geisslinger
Journal:  Orthopade       Date:  2003-12       Impact factor: 1.087

10.  Neuroinflammation, microglia and implications for anti-inflammatory treatment in Alzheimer's disease.

Authors:  Daniela L Krause; Norbert Müller
Journal:  Int J Alzheimers Dis       Date:  2010-06-14
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.